Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1395579 | European Journal of Medicinal Chemistry | 2007 | 7 Pages |
A series of 3- and 5-aryl-1,2,4-oxadiazole derivatives were prepared and tested for anticonvulsant activity in a variety of models. These 1,2,4-oxadiazoles exhibit considerable activity in both pentylenetetrazole (PTZ) and maximal electroshock seizure (MES) models. Compound 10 was protective in the PTZ model in rats with an oral ED50 of 25.5 mg/kg and in the MES model in rats with an oral ED50 of 14.6 mg/kg. Neurotoxicity (rotarod) was observed with an ED50 of 335 mg/kg. We found several oxadiazoles that acted as selective GABA potentiating compounds with no interaction to the benzodiazepine binding site.
Graphical abstractNew 3- and 5-aryl-1,2,4-oxadiazole derivatives are described that act as selective GABA potentiating compounds with no interaction to the benzodiazepine binding site and compound 10 was found to be most effective.Figure optionsDownload full-size imageDownload as PowerPoint slide